Form 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D) OF THE

THE SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): September 20, 2006

 

ALEXION PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-27756   13-3648318

(State or other jurisdiction of

incorporation or organization)

   (Commission File Number)  

(I.R.S. Employer

Identification No.)

352 Knotter Drive, Cheshire, Connecticut 06410

(Address of Principal Executive Offices) (Zip Code)

Registrant’s telephone number, including area code: (203) 272-2596

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Item 8.01 Other Events.

On September 20, 2006, Alexion Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that the Company has submitted a Biologics License Application with the U.S. Food and Drug Administration for its lead product candidate Soliris™ (eculizumab), as a treatment for patients diagnosed with paroxysmal nocturnal hemoglobinuria, a rare life-threatening genetic blood disorder (“PNH”). A copy of that press release is furnished as Exhibit 99.1 to this Form 8-K.

On September 26, 2006, the Company issued a press release announcing that Alexion Europe, a wholly-owned subsidiary of the Company, has submitted a Market Authorization Application to the European Medicines Evaluation Agency for Soliris™ (eculizumab) as a treatment for patients diagnosed with PNH. A copy of that press release is furnished as Exhibit 99.2 to this

Form 8-K.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

 

99.1 Press Release issued by Alexion Pharmaceuticals, Inc. on September 20, 2006.

 

99.2 Press Release issued by Alexion Pharmaceuticals, Inc. on September 26, 2006.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ALEXION PHARMACEUTICALS, INC.
Date: October 5, 2006   By:  

/s/ Thomas I. H. Dubin

  Name:   Thomas I. H. Dubin
  Title:   Senior Vice President and General Counsel

Index to Exhibits

 

Exhibit No.  

Description

99.1   Press Release issued by Alexion Pharmaceuticals, Inc. on September 20, 2006.
99.2   Press Release issued by Alexion Pharmaceuticals, Inc. on September 26, 2006.